TNF-α Pathway: Clinical Trial & Pipeline Intelligence — Q1 2026

Executive Summary

Key Events by Therapeutic Class

Directly TNF-α-Targeted Therapies

• XPro1595 (INmune Bio): FDA End-of-Phase 2 meeting confirmed regulatory alignment on an integrated Phase 2b/3 registration pathway in early Alzheimer's disease, with CDR-SB as the sole primary endpoint, inflammation-based biomarker enrichment accepted, and approximately 1,000-participant program design cleared with no objection.^[1]
• NAV-240 (Navigator Medicines): FDA IND clearance received for a Phase 2a trial of the OX40L/TNF-α bispecific antibody in moderate-to-severe hidradenitis suppurativa, with dosing initiated Q1 2026.^[11]
• NAV-242 (Navigator Medicines): Australian HREC approval received for the Phase 1 first-in-human program of the next-generation half-life-extended OX40L/TNF-α bispecific antibody, with SAD results expected Q4 2026.^[11]
• SOR102 (Sorriso Pharma): Phase 1 first-in-human data published for the oral bispecific anti-TNF/IL-23 antibody, demonstrating 43–56% clinical response rates at day 42 in UC patients versus 17% for placebo.^[7]
• Adalimumab (AbbVie): The ADVISE trial demonstrated superiority over conventional immunosuppression for corticosteroid sparing at 6 months (69% vs. 54%; p=0.029) and corticosteroid discontinuation at 12 months (55% vs. 40%; p=0.028) in non-infectious uveitis.^[2]
• Infliximab / Adalimumab (J&J / AbbVie): Post-hoc analysis of 300 UC patients from HIBISCUS I/II and GARDENIA found anti-TNF therapy drives a proximal-to-distal colonic healing pattern, and combined MES + PRO2 endpoint outperformed PRO2 alone (28.6% vs. 13.3%; p=0.006).^[8]
• Certolizumab Pegol (UCB): Post-hoc analysis of 930 RA patients from the REALISTIC trial confirmed that high rheumatoid factor levels (≥180 kU/L) do not diminish CZP efficacy, and that prior TNFi failure does not predict reduced CZP response.^[3]
• Infliximab + Azathioprine vs. Rifaximin + Azathioprine (J&J / Generic): Prospective cohort of 130 IBD patients demonstrated IFX+AZA is superior for acute TNF-α-driven inflammation control during induction, while RIF+AZA offers superior mucosal healing and oxidative balance, supporting a two-phase induction–maintenance strategy.^[10]

TNF-α Pathway-Adjacent Pipeline (Upstream Targets)

• GS-6791 / NX-3911 (Gilead+Nurix / Sanofi+Nurix): Corporate update highlighted GS-6791, an oral IRAK4 degrader in Phase 1 with results expected 2026, and NX-3911, an oral STAT6 degrader in IND-enabling studies with an IND filing anticipated in 2026, both targeting upstream inflammatory signaling nodes.^[12]

Repurposed/Adjunctive Agents Modulating TNF-α

• Fluoxetine (Generic): A single-center double-blind RCT found 40mg/day significantly reduced vasopressor duration (6.2 vs. 7.9 days; p<0.001), ICU length of stay, and inflammatory markers including TNF-α and IL-1 by day 7 in severe sepsis patients.^[4]
• Montelukast (Generic): An open-label RCT found montelukast significantly reduced 28-day ICU mortality versus control (23.3% vs. 56.7%; p=0.024) and significantly reduced TNF-α and MDA in sepsis patients.^[5]
• Colchicine (Generic): An observational pilot study found 0.5mg/day reduced IL-8 by 65.5% (p=0.001) and IL-6 over 2 weeks in HFpEF patients, with secondary improvements in anxiety, depression, and quality of life at 1 month.^[9]
• Maraviroc (ViiV Healthcare): A proof-of-concept Phase 2 RCT found maraviroc reduced COVID-19 progression 2.8× versus standard of care and significantly reduced TNF-α and IL-6 at day 7, with no Grade 3–4 adverse events in the maraviroc group.^[6]

Period Overview

The first ten weeks of 2026 delivered notable TNF-alpha clinical activity across neurology, dermatology, rheumatology, gastroenterology, and critical care — headlined by XPro1595's FDA-aligned Phase 2b/3 registration pathway in Alzheimer's disease, the first OX40L/TNF-α bispecific program advancements, and an oral bispecific anti-TNF/IL-23 Phase 1 readout in ulcerative colitis.

• Conventional Anti-TNF Biologics (adalimumab, infliximab, certolizumab pegol): Bind and neutralize soluble and transmembrane TNF-α via IgG antibody or PEGylated Fab, delivering rapid suppression of TNF-α-driven inflammatory cascades with a two-decade evidence base. Indiscriminate tmTNF blockade limits CNS applications, creates class-wide safety overlap, and biosimilar competition is eroding commercial differentiation across established indications.
• Selective Soluble TNF Inhibitors (XPro1595): Dominant-negative mechanism neutralizes sTNF while sparing tmTNF signaling — enabling CNS-directed therapy that conventional biologics cannot safely pursue. Structurally novel with no class comparators; clinical track record in neurodegeneration is unproven pending the integrated Phase 2b/3 trial outcome.
• Bispecific Antibodies (NAV-240, NAV-242, SOR102): Simultaneously block TNF-α and a second inflammatory mediator (OX40L or IL-23) to amplify efficacy beyond TNF inhibition alone; SOR102's oral formulation adds a route-of-administration differentiator over injectable biologics. Greater manufacturing complexity and less established long-term safety than monoclonal predecessors; superiority over TNF monotherapy not yet confirmed in registration-track data.
• Upstream NF-κB/TNF-α Pathway Modulators (GS-6791, NX-3911): Oral protein degraders targeting IRAK4 or STAT6 upstream of TNF-α transcription, potentially suppressing broader inflammatory programs and addressing cytokine redundancy limitations of direct inhibition. Earliest-stage in this report with no published clinical efficacy data; off-target degradation risk requires Phase 1 characterization.
• Repurposed/Adjunctive Agents (fluoxetine, montelukast, colchicine, and others): Reduce TNF-α as a downstream effect of established mechanisms — NF-κB inhibition, inflammasome blockade, ROS scavenging; benefit from known safety profiles in primary indications. Produce indirect and modest TNF-α modulation only; generic status removes direct commercial opportunity.

INmune Bio's February 12, 2026 FDA End-of-Phase 2 alignment on an integrated Phase 2b/3 pathway for XPro1595 in early Alzheimer's disease — with CDR-SB as the sole primary endpoint and inflammation-based biomarker enrichment accepted — is the most strategically significant development of the period and the first FDA-aligned registration pathway for any TNF-directed neurodegeneration therapy.^[1]

Navigator Medicines advanced NAV-240 (Phase 2a IND-cleared, dosing Q1 2026) and NAV-242 (Phase 1 HREC-approved, FIH initiated Q1 2026) simultaneously in HS and IBD, while SOR102's oral bispecific Phase 1 readout in UC (43–56% response vs. 17% placebo) validated dual TNF/IL-23 inhibition with an oral delivery advantage.^[11][7] Nurix Therapeutics highlighted GS-6791 (IRAK4 degrader, Gilead, Phase 1) and NX-3911 (STAT6 degrader, Sanofi, IND-enabling) as upstream alternatives targeting NF-κB-driving kinases before cytokine production.^[12]

Established biologics continued to accumulate evidence in new contexts: certolizumab's Fc-free structure validated in high-RF RA (REALISTIC, n=930), adalimumab confirmed superior corticosteroid sparing in non-infectious uveitis (ADVISE), and HIBISCUS/GARDENIA data refined UC endpoint strategy.^[3][2][8] Repurposed agent data across critical care and cardiometabolic indications reinforced TNF-alpha as a broadly relevant inflammatory biomarker beyond autoimmune indications.

Therapeutic Landscape

Indication Deep-Dive

Alzheimer's Disease

XPro1595 (pegipanermin) — FDA End-of-Phase 2 Alignment

The most strategically significant development of the reporting period is INmune Bio's announcement on February 12, 2026 that it received official End-of-Phase 2 meeting minutes from the FDA confirming alignment on an integrated Phase 2b/3 registration pathway for XPro1595 in early Alzheimer's disease.^[1]

XPro1595 (pegipanermin) is a selective soluble TNF inhibitor employing a dominant-negative TNF approach — it neutralizes sTNF without affecting transmembrane TNF signaling or either TNF receptor. This selectivity is mechanistically critical for CNS applications: conventional pan-TNF inhibitors have historically been contraindicated in neurological indications due to tmTNF's role in neuroprotection, oligodendrocyte survival, and synaptic plasticity.

The EOP2 meeting achieved alignment on several parameters that collectively remove major regulatory uncertainty:

• Primary endpoint: CDR-SB (Clinical Dementia Rating Sum of Boxes) accepted as the sole primary endpoint, consistent with recent Alzheimer's regulatory precedent set by lecanemab and donanemab
• Biomarker enrichment strategy: FDA accepted an inflammation-based enrichment approach using hsCRP, ESR, HbA1c, and APOE4 status — enabling enrollment of patients most likely to respond to TNF-targeting
• Trial design: Integrated Phase 2b/3 design cleared with no objection; approximately 1,000 participants planned
• No new safety requirements specific to the CNS indication were flagged

XPro1595 Biomarker Enrichment Strategy — hsCRP, ESR, HbA1c, APOE4 — FDA accepted

FDA accepted an inflammation-based multi-marker enrichment strategy for XPro1595 trial enrollment in Alzheimer's disease. This is the first precedent for inflammation-based patient selection in an Alzheimer's registration trial — a meaningful validation of neuroinflammation as a targetable disease driver.

XPro1595 represents the only TNF-directed program with an active FDA-aligned registration pathway in neurodegeneration. If successful, it would establish selective sTNF inhibition as a validated mechanism in AD, with potential read-through to other neurodegenerative indications (Parkinson's disease, ALS) where TNF-alpha-driven neuroinflammation has been implicated.

Hidradenitis Suppurativa

NAV-240 and NAV-242 — OX40L/TNF-α Bispecific Program Advances

Navigator Medicines announced on January 8, 2026 two parallel clinical milestones for its OX40L/TNF-α bispecific antibody program in hidradenitis suppurativa.^[11]

NAV-240 received FDA IND clearance for a Phase 2a trial in moderate-to-severe HS, with dosing initiated Q1 2026. NAV-240 is a bispecific antibody that simultaneously blocks OX40L and TNF-α — two inflammatory mediators that together drive the chronic, relapsing inflammatory cascades characteristic of HS. The dual blockade mechanism is designed to deliver greater disease control than TNF inhibition alone, particularly in patients with inadequate response to current anti-TNF biologics. Phase 1 safety and tolerability data were positive, and Phase 1b multiple ascending dose results are expected to be shared at an upcoming medical congress.

NAV-242 received Australian Human Research Ethics Committee (HREC) approval for a Phase 1 first-in-human program. NAV-242 is an engineered next-generation version of NAV-240 with half-life extension, designed to optimize plasma exposure and reduce dosing frequency. The SAD program in healthy volunteers and HS patients was initiated Q1 2026, with single ascending dose results expected Q4 2026. NAV-242's broader indication scope — including Crohn's disease and ulcerative colitis alongside HS — suggests Navigator is positioning this as a platform molecule for OX40L/TNF-α dual blockade across multiple immune-mediated indications.

NAV-240 Phase 2a — HS Indication — FDA IND Cleared; Phase 2a Dosing Initiated Q1 2026

NAV-240 becomes the first OX40L/TNF-α bispecific antibody to enter a registrational-track Phase 2a trial. HS represents a high-unmet-need indication where TNF monotherapy has limited long-lived efficacy; dual OX40L/TNF-α blockade addresses two non-redundant inflammatory drivers simultaneously.

Ulcerative Colitis

SOR102: Oral Bispecific Anti-TNF/IL-23

Sorriso Pharma reported first-in-human Phase 1 data for SOR102, an oral bispecific single-domain antibody that dually inhibits TNF-α and IL-23p19.^[7] The trial enrolled both healthy volunteers and ulcerative colitis patients across multiple dose cohorts.

SOR102 Clinical Response Rate (UC, Day 42) — 43–56% vs. 17% placebo

UC patients receiving SOR102 achieved 43–56% clinical response rates at day 42 depending on dose cohort, compared to 17% for placebo. Safety and tolerability were favorable across all dose levels. Phase 2 planning is underway.

The oral route of administration is the primary differentiating factor: current biologic standards for UC (infliximab, adalimumab, vedolizumab) are injectable or infused. An oral bispecific with dual TNF/IL-23 inhibition could significantly expand the addressable market and improve patient adherence — if efficacy translates in Phase 2.

Anti-TNF Endoscopic Healing Patterns — HIBISCUS/GARDENIA Post-hoc

A post-hoc analysis of 300 UC patients from the HIBISCUS I, HIBISCUS II, and GARDENIA trials examined the spatial healing pattern induced by anti-TNF therapy (infliximab and adalimumab).^[8] Key findings:

• Anti-TNF therapy induces a proximal-to-distal colonic healing pattern, with more complete healing occurring in proximal segments first
• Conventional Mayo Endoscopic Score (MES) outperforms segmental scoring for detecting anti-TNF treatment effects at standard timepoints
• Combined MES + PRO2 endpoint outperformed PRO2 alone (28.6% vs. 13.3%; p=0.006)

Combined MES + PRO2 Endpoint Advantage — 28.6% vs. 13.3% (p=0.006)

In 300 UC patients treated with anti-TNF agents, a combined MES + PRO2 composite endpoint captured significantly more treatment responders than PRO2 alone. This has direct implications for endpoint selection in future UC trial designs targeting anti-TNF mechanisms.

These findings have methodological implications for how future anti-TNF trials in UC should structure their endoscopic endpoints — relevant for any program designing a registration study in this space.

Inflammatory Bowel Disease

IFX+AZA versus Rifaximin+AZA: Two-Phase Strategy for IBD

A prospective cohort study of 130 IBD patients compared infliximab plus azathioprine (IFX+AZA) against rifaximin plus azathioprine (RIF+AZA) across 12 weeks of treatment.^[10] The study assessed intestinal barrier function, mucosal repair markers, inflammatory factors, and oxidative stress indices.

Key findings:

• IFX+AZA rapidly reduced pro-inflammatory cytokines (TNF-α, CRP) and mucosal injury markers, but elevated lipopolysaccharide (LPS) levels — suggesting acute anti-inflammatory efficacy at the cost of intestinal barrier disruption
• RIF+AZA enhanced mucosal repair (via EGF and TGF-β1 modulation) and antioxidant capacity, with less liver enzyme elevation — positioning it as a superior maintenance strategy

IBD Two-Phase Strategy — IFX+AZA for induction; RIF+AZA for maintenance

In 130 IBD patients, IFX+AZA was superior for acute TNF-α-driven inflammation control during induction, while RIF+AZA demonstrated superior mucosal healing and oxidative balance for maintenance. The data support a sequential two-phase approach rather than a single sustained regimen.

The clinical implication is a complementary rather than competitive positioning for these two combination strategies — anti-TNF induction followed by microbiota-modulating maintenance — which may be relevant to biologics-to-maintenance transition planning in IBD management protocols.

Rheumatoid Arthritis

Certolizumab Pegol — REALISTIC Post-hoc Analysis

A post-hoc analysis of 930 RA patients from the REALISTIC trial, published in RMD Open (2026), addressed a clinically meaningful question about certolizumab pegol's utility in difficult-to-treat RA populations.^[3]

Key findings:

• High rheumatoid factor levels (≥180 kU/L) do not diminish CZP efficacy — historically, high-RF patients have been considered to have worse prognoses and potentially reduced biologic response
• Prior TNFi failure does not predict reduced CZP response — CZP achieved similar ACR response rates in patients who had previously failed another TNF inhibitor vs. TNFi-naive patients

CZP Efficacy — High RF Threshold — ≥180 kU/L RF does not reduce efficacy

In 930 RA patients, certolizumab pegol maintained consistent ACR response rates at RF levels ≥180 kU/L — a threshold associated with poor prognosis and historically lower expected biologic response. CZP's Fc-free structure may partially explain this RF-independent activity.

The mechanistic rationale involves CZP's unique PEGylated Fab structure, which lacks an Fc region and therefore cannot itself be bound by rheumatoid factor — unlike full IgG antibodies such as adalimumab and infliximab. This structural property may contribute to its RF-independent clinical performance.

Non-infectious Uveitis

Adalimumab — ADVISE Trial

The ADVISE trial randomized 227 patients with non-infectious intermediate, posterior, or panuveitis to adalimumab versus conventional immunosuppression (methotrexate or mycophenolate mofetil).^[2]

ADVISE: Corticosteroid Sparing at 6 Months — 69% vs. 54% (p=0.029)

Adalimumab achieved statistically superior corticosteroid sparing vs. conventional immunosuppression at 6 months in non-infectious uveitis (69% vs. 54%; p=0.029). At 12 months, corticosteroid discontinuation rates were 55% vs. 40% (p=0.028), strengthening the case for earlier anti-TNF deployment in ocular inflammatory disease.

This data strengthens the evidence base for adalimumab as the preferred biologic for non-infectious uveitis — an indication where it already carries FDA approval but where real-world use has sometimes lagged behind conventional immunosuppression due to prescriber familiarity. The 6- and 12-month superiority data support an earlier-line positioning argument.

Pipeline: Upstream NF-κB/TNF-α Modulators

GS-6791 (IRAK4 Degrader) and NX-3911 (STAT6 Degrader) — Nurix Pipeline Update

Nurix Therapeutics' January 12, 2026 corporate update highlighted two partnered oral degrader programs with direct relevance to TNF-alpha biology.^[12]

GS-6791 is an oral IRAK4 (Interleukin-1 Receptor-Associated Kinase 4) degrader co-developed with Gilead Sciences. IRAK4 is a serine/threonine kinase that acts as an obligate upstream signal transducer for all TLR and IL-1R family receptors, including those that drive NF-κB activation and downstream TNF-alpha transcription. By degrading IRAK4 rather than simply inhibiting it, GS-6791 aims to achieve more complete and durable suppression of NF-κB/TNF-α signaling than kinase inhibitors alone. The program is currently in Phase 1 in healthy volunteers, with results expected in 2026. Nurix retains a 50/50 U.S. co-development option.

NX-3911 is an oral STAT6 degrader partnered with Sanofi, targeting the IL-4/IL-13 signaling axis — a key driver of type 2 inflammatory disease that intersects with and amplifies TNF-alpha-driven cascades in atopic and allergic conditions. NX-3911 is in IND-enabling studies, with an IND filing anticipated in 2026.

GS-6791 (IRAK4 Degrader) Phase 1 — Phase 1 Ongoing; Results Expected 2026

GS-6791 targets IRAK4, the upstream kinase responsible for NF-κB activation and TNF-α transcription. As a protein degrader rather than a kinase inhibitor, it may achieve more durable pathway suppression. Phase 1 results in 2026 will be the first human data for an oral IRAK4 degrader in I&I.

These programs represent the leading edge of upstream pathway modulation as a complement or alternative to direct TNF-α neutralization. If GS-6791 Phase 1 data demonstrate tolerable safety and target engagement, it would represent a meaningful mechanistic step beyond current anti-TNF biologics for autoimmune indications.

Critical Care and Perioperative Medicine

Fluoxetine in Severe Sepsis

A single-center, double-blind RCT (n=46) evaluated fluoxetine 40mg/day as an adjunct in ICU patients with severe sepsis.^[4]

Fluoxetine: Vasopressor Duration Reduction — 6.2 vs. 7.9 days (p<0.001)

Fluoxetine 40mg/day significantly reduced vasopressor dependency duration (6.2 vs. 7.9 days; p<0.001) and ICU length of stay in severe sepsis. TNF-α and IL-1 levels were significantly reduced by day 7. No statistically significant difference in 28-day mortality was observed (8.7% vs. 17.4%; p=0.381), though the trial was underpowered for mortality.

The mechanism is immunometabolic: SSRIs including fluoxetine inhibit NF-κB activation in macrophages, reducing downstream TNF-α and IL-1β transcription. The small sample size limits mortality interpretation, but the vasopressor and inflammatory marker data support a biologically plausible anti-inflammatory effect.

Montelukast in Sepsis

An open-label RCT (n=90 ICU patients) compared montelukast against CoQ10 as adjunctive sepsis therapy.^[5]

Montelukast: 28-Day Mortality Reduction — 23.3% vs. 56.7% (p=0.024)

Montelukast significantly reduced 28-day ICU mortality vs. control (23.3% vs. 56.7%; p=0.024) and significantly reduced TNF-α and MDA. No adverse effects were observed with montelukast, while 20% of CoQ10 patients experienced hypotension. Open-label design and small sample size require replication in a blinded trial.

Cardiometabolic Disease

Colchicine in HFpEF

An observational pilot study (n=126) examined colchicine 0.5mg/day over 2 weeks in heart failure with preserved ejection fraction.^[9]

Colchicine: IL-8 Reduction in HFpEF — 65.5% IL-8 reduction (p=0.001)

Colchicine 0.5mg/day reduced IL-8 by 65.5% (p=0.001) and IL-6 over 2 weeks in HFpEF patients. Secondary improvements in anxiety (HAMA), depression (HAMD), and quality of life (KCCQ) were also observed at 1 month. Observational design limits causal interpretation; a randomized trial is needed.

Infectious Disease

Maraviroc in Hospitalized COVID-19

A proof-of-concept Phase 2 RCT (n=33) examined the CCR5 antagonist maraviroc as an adjunct in non-severe hospitalized COVID-19 patients.^[6]

Maraviroc: COVID-19 Progression Reduction — 2.8× less progression vs. standard of care

Maraviroc reduced COVID-19 progression 2.8× vs. standard of care and significantly reduced TNF-α and IL-6 at day 7. No Grade 3–4 adverse events occurred in the maraviroc group, vs. three ICU admissions in controls. Small sample size requires confirmation in a larger randomized trial.

Maraviroc's primary mechanism (CCR5 blockade) reduces immune cell trafficking to sites of inflammation and indirectly suppresses pro-inflammatory cytokine cascades including TNF-α and IL-6. This positions it as a potential cytokine storm modulator with an established safety profile from its HIV indication.

Competitive Intelligence Highlights

1. XPro1595 Establishes Selective TNF Inhibition as a Neurological Drug Class

INmune Bio's regulatory milestone establishes XPro1595 as the first TNF-directed therapy with a credible registration pathway in neurodegeneration.^[1] If the integrated Phase 2b/3 trial succeeds, it creates a new drug class — selective sTNF inhibitors — with CNS exclusivity that conventional anti-TNF biologics cannot access due to tmTNF signaling requirements. Competitors would need to develop their own selective sTNF platforms to participate in this space.

2. Navigator Medicines Opens a New Front in Bispecific Antibody Development for HS

The simultaneous advancement of NAV-240 (Phase 2a, FDA-cleared) and NAV-242 (Phase 1, HREC-approved) represents a coordinated dual-program strategy for OX40L/TNF-α bispecific antibodies across HS and IBD indications.^[11] Navigator is building a next-generation franchise in indications where TNF monotherapy has shown limited durability. If Phase 2a data for NAV-240 in HS demonstrate superior efficacy to current anti-TNF SOC, Navigator would become the first mover in OX40L/TNF-α bispecific therapy — a position that would be difficult for competitors to replicate given the IND timeline gaps.

3. SOR102 Signals a Shift Toward Oral Biologics in IBD

The SOR102 Phase 1 readout is the first human data for an oral bispecific anti-TNF/IL-23 agent.^[7] At 43–56% day-42 clinical response rates in UC patients, the signal is comparable to early-phase injectable biologic data. If Phase 2 confirms these findings, SOR102 would position Sorriso as a first-mover in oral bispecific biologics for IBD — a market segment with significant unmet need given the injection burden of current SOC.

4. Upstream IRAK4 Degradation Represents a Pipeline Bet Against TNF-α Pathway Redundancy

GS-6791's IRAK4 degradation mechanism addresses a long-standing limitation of direct TNF-α inhibition: cytokine redundancy, whereby other inflammatory mediators compensate when TNF-α is suppressed.^[12] By targeting an obligate upstream kinase shared by multiple TLR/IL-1R pathways, GS-6791 theoretically blocks a broader inflammatory program than any individual cytokine inhibitor. Phase 1 results expected in 2026 will be closely watched as proof-of-concept data for upstream degrader strategies in I&I.

5. Certolizumab Pegol's Fc-Free Structure Gains Evidence-Based Differentiation in RA

The REALISTIC post-hoc data provides the strongest published evidence that CZP's lack of an Fc region translates into clinical advantages in high-RF RA populations.^[3] This is meaningful competitive differentiation in a sub-segment (high-RF, TNFi-experienced RA) that is typically harder to treat. UCB has a data asset here that competitors with Fc-containing anti-TNF antibodies cannot replicate without their own structural differentiation.

6. Repurposed Agents Validate TNF-alpha as a Multi-Indication Inflammatory Biomarker

The breadth of repurposed drug data in this period — fluoxetine, montelukast, colchicine, maraviroc — collectively strengthens the case for TNF-alpha as a universal inflammatory biomarker and mechanistic target across critical care, cardiometabolic, and infectious disease settings.^[4][5][6] This expands the potential market for TNF-alpha diagnostic tools and enrichment strategies beyond autoimmune indications.

7. Adalimumab Continues to Accumulate Data in Ophthalmology

The ADVISE trial data^[2] reinforces adalimumab's positioning as the standard anti-TNF agent in non-infectious uveitis at a time when biosimilar competition is primarily concentrated in RA and PsO. Ophthalmology represents a comparatively protected indication segment where originator adalimumab can maintain premium positioning — especially given the lower prescription volumes and specialist prescribing patterns that make biosimilar formulary mandates less operationally feasible.

Methodology and Sources

This report covers clinical trial readouts, regulatory milestones, and published analyses from January 1, 2026 through March 11, 2026 relevant to the TNF-alpha pathway. Thirteen distinct agents or drug combinations are covered across oncology-adjacent indications, rheumatology, gastroenterology, neurology, dermatology, and critical care.

Research approach:

• Primary literature: Published RCTs, post-hoc analyses, and Phase 1–3 trial readouts indexed in PubMed and EMBASE during the reporting window
• Regulatory filings: FDA meeting minutes and official communications (INmune Bio press release and SEC filing, February 12, 2026)
• Corporate disclosures: Navigator Medicines press release (January 8, 2026), Nurix Therapeutics corporate pipeline update (January 12, 2026)
• Journal sources: RMD Open, Ophthalmology, Inflammatory Bowel Diseases, Pakistan Journal of Pharmaceutical Sciences, and critical care journals

Scope limitations:

• This report covers clinical trial and pipeline intelligence only. Payer formulary positioning, market access, and commercial landscape data are covered in the companion Market Access Landscape edition.
• Repurposed agent data (fluoxetine, montelukast, colchicine, maraviroc) represents emerging or exploratory evidence and should not be interpreted as established clinical practice recommendations.
• NAV-240 and NAV-242 data are sourced from company press releases; independent clinical publication of Phase 1 results has not yet occurred as of the preparation date.

Reporting period: January 1, 2026 – March 11, 2026

Analyst: Batu Akkas — Chief Pipeline Intelligence Officer, Inflection Labs

This report reflects data and published analyses current as of the preparation date. Clinical evidence summaries are for intelligence purposes only and do not constitute clinical or investment advice.

References

[1] INmune Bio, Inc. "INmune Bio Receives FDA End-of-Phase 2 Meeting Minutes Confirming Integrated Registration Pathway for XPro1595 in Early Alzheimer's Disease." Press Release, February 12, 2026. Link

[2] "Adalimumab versus Conventional Immunosuppression for Uveitis (ADVISE) Trial." Ophthalmology, March 2026. Link

[3] "Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trial." RMD Open, January 30, 2026. Link

[4] "Effect of fluoxetine on organ dysfunction and mortality in severe sepsis." PLOS ONE, January 21, 2026. Link

[5] "The clinical outcome of Montelukast versus co-enzyme Q10 in adult patients with sepsis: A randomized controlled clinical trial." Journal of Critical Care, February 2026. Link

[6] "Maraviroc treatment for hospitalized participants with non-severe COVID-19 at risk of progression: a randomized, proof-of-concept clinical trial." Journal of Microbiology, Immunology and Infection, February 2026. Link

[7] "Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial." Lancet Gastroenterology & Hepatology, January 2026. Link

[8] "Anti-TNF Therapies Promote a Proximal-to-Distal Healing Pattern in Moderate-to-Severe Ulcerative Colitis." Inflammatory Bowel Diseases, January 2026. Link

[9] "Colchicine reduces inflammatory cytokines and improves symptoms in HFpEF: an observational pilot study." Frontiers in Medicine, January 15, 2026. Link

[10] "Azathioprine combined with either rifaximin or infliximab for inflammatory bowel disease: Differential impacts on intestinal barrier function, inflammatory response and stress injury." Pakistan Journal of Pharmaceutical Sciences, March 2026. Link

[11] Navigator Medicines. "Navigator Medicines Accelerates Anti OX-40L and TNFα Bispecific Antibody Clinical Development Pipeline into Phase 2a and First-in-Human Trials." Press Release, January 8, 2026. Link

[12] Nurix Therapeutics. "Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases." Press Release, January 12, 2026. Link